Sana BiotechnologySANA
About: Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
Employees: 328
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
54% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 37
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
0.01% more ownership
Funds ownership: 66.92% [Q1] → 66.93% (+0.01%) [Q2]
4% less funds holding
Funds holding: 152 [Q1] → 146 (-6) [Q2]
19% less call options, than puts
Call options by funds: $6.73M | Put options by funds: $8.35M
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
45% less capital invested
Capital invested by funds: $1.47B [Q1] → $810M (-$665M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Citigroup Samantha Semenkow 39% 1-year accuracy 7 / 18 met price target | 285%upside $15 | Buy Maintained | 9 Aug 2024 |
HC Wainwright & Co. Emily Bodnar 35% 1-year accuracy 38 / 108 met price target | 182%upside $11 | Buy Maintained | 9 Aug 2024 |
